Søke etter navn:
A B C D E F G H I J K L M N O P R S T U V W X Y Z
VPXL
VPXL
VPXL stimulates natural growth of cells of a cavernous body of penis increasing its size.
Pakke
Pris
Per Flasker
Besparelser
Bestille
60 caps x 1 flaske
$45.99
$45.99
$0.00
60 caps x 2 flasker
$85.99
$42.99
$6.00
60 caps x 3 flasker
$114.99
$38.33
$22.98

Produktbeskrivelse

Common use

VPXL is 100% natural product without any known side effects that stimulates natural growth of cells of a cavernous body of penis increasing its size. All growth is permanent.



Dosage and direction

Recommended dosage of 2 tablets should be taken once daily after a meal.



Precautions

VPXL is to be used only by the consumers for whom it is recommended. Do not give it to people even if they similar symptoms.



Contraindications

No contraindications are described for this herbal supplement. Consult your practitioner if any condition bothers you.



Possible side effect

There have been no reported side effects associated with VPXL.



Missed dose

Take the forgotten dose as soon as possible, skip the next dose according to your schedule if it is almost time for it. Never double the dose of this supplement.



Overdose

No signs of overdose are known. If you suppose that you took too much of it consult your practitioner.



Storage

Store VPXL at room temperature, between 68-77 F (20-25 C) away from heat, moisture, light, children and pets.



Disclaimer

All products presented at this site are not intended to diagnose, treat, cure, or prevent any disease. Don't hesitate to consult your health care practitioner before taking any herbal supplement.

 

GRATIS FRAKT
GRATIS PILLER
10 % RABATT
Nyheter
2025-03-13
There are three main reasons body is going - money, bureaucracy and control, says Nick Triggle
2025-03-13
As part of Your Voice, Your BBC, we answer questions from you on government plans to scrap NHS England.
2025-03-13
It can be taken at home on a daily basis, but it is only patients for who have tried all other options. ...
2025-03-13
Children under five constituted more than 40% of the cases reported in Europe and Central Asia last year.